Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma

Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. To address this challenge, aptamers were selected by cell-SELEX (Systematic E...

Descripción completa

Detalles Bibliográficos
Autores principales: Champanhac, Carole, Teng, I-Ting, Cansiz, Sena, Zhang, Liqin, Wu, Xiaoqiu, Zhoa, Zilong, Fu, Ting, Tan, Weihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658478/
https://www.ncbi.nlm.nih.gov/pubmed/26603187
http://dx.doi.org/10.1038/srep16788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658478/
https://www.ncbi.nlm.nih.gov/pubmed/26603187
http://dx.doi.org/10.1038/srep16788

Ejemplares similares